Cargando…
EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay
EGFL7 is a secreted angiogenic factor, which in contrast to the well-known secreted angiogenic molecules VEGF and FGF-2, is almost exclusively expressed by endothelial cells and may act in an autocrine fashion. Prior studies have shown EGFL7 to mediate its angiogenic effects by interfering with the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960138/ https://www.ncbi.nlm.nih.gov/pubmed/24647208 http://dx.doi.org/10.1371/journal.pone.0091849 |
_version_ | 1782308122810908672 |
---|---|
author | Takeuchi, Kimio Yanai, Ryoji Kumase, Fumiaki Morizane, Yuki Suzuki, Jun Kayama, Maki Brodowska, Katarzyna Nakazawa, Mitsuru Miller, Joan W. Connor, Kip M. Vavvas, Demetrios G. |
author_facet | Takeuchi, Kimio Yanai, Ryoji Kumase, Fumiaki Morizane, Yuki Suzuki, Jun Kayama, Maki Brodowska, Katarzyna Nakazawa, Mitsuru Miller, Joan W. Connor, Kip M. Vavvas, Demetrios G. |
author_sort | Takeuchi, Kimio |
collection | PubMed |
description | EGFL7 is a secreted angiogenic factor, which in contrast to the well-known secreted angiogenic molecules VEGF and FGF-2, is almost exclusively expressed by endothelial cells and may act in an autocrine fashion. Prior studies have shown EGFL7 to mediate its angiogenic effects by interfering with the Notch pathway and/or via the intronic miR126. Less is known about its effects on VEGF signaling. We wanted to investigate the role of epidermal growth factor-like domain 7 (EGFL7) in VEGF-driven angiogenesis using an ex vivo Matrigel-embedded mouse eye cup assay and siRNA mediated knockdown of EGFL7 by siRNA. Our results suggested that VEGF-induced vascular tube formation was significantly impaired after siRNA downregulation of EGFL7. In addition, knockdown of EGFL7 suppressed VEGF upregulation of phospho-Akt and phospho-Erk(1/2) in endothelial cells, but did not alter VEGFR phosphorylation and neuropilin-1 protein expression or miR126 expression. Thus, in conclusion, EGFL7 is required for VEGF upregulation of the Akt/Erk (1/2) pathway during angiogenesis, and may represent a new therapeutic target in diseases of pathological neovascularization. |
format | Online Article Text |
id | pubmed-3960138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39601382014-03-27 EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay Takeuchi, Kimio Yanai, Ryoji Kumase, Fumiaki Morizane, Yuki Suzuki, Jun Kayama, Maki Brodowska, Katarzyna Nakazawa, Mitsuru Miller, Joan W. Connor, Kip M. Vavvas, Demetrios G. PLoS One Research Article EGFL7 is a secreted angiogenic factor, which in contrast to the well-known secreted angiogenic molecules VEGF and FGF-2, is almost exclusively expressed by endothelial cells and may act in an autocrine fashion. Prior studies have shown EGFL7 to mediate its angiogenic effects by interfering with the Notch pathway and/or via the intronic miR126. Less is known about its effects on VEGF signaling. We wanted to investigate the role of epidermal growth factor-like domain 7 (EGFL7) in VEGF-driven angiogenesis using an ex vivo Matrigel-embedded mouse eye cup assay and siRNA mediated knockdown of EGFL7 by siRNA. Our results suggested that VEGF-induced vascular tube formation was significantly impaired after siRNA downregulation of EGFL7. In addition, knockdown of EGFL7 suppressed VEGF upregulation of phospho-Akt and phospho-Erk(1/2) in endothelial cells, but did not alter VEGFR phosphorylation and neuropilin-1 protein expression or miR126 expression. Thus, in conclusion, EGFL7 is required for VEGF upregulation of the Akt/Erk (1/2) pathway during angiogenesis, and may represent a new therapeutic target in diseases of pathological neovascularization. Public Library of Science 2014-03-19 /pmc/articles/PMC3960138/ /pubmed/24647208 http://dx.doi.org/10.1371/journal.pone.0091849 Text en © 2014 Takeuchi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Takeuchi, Kimio Yanai, Ryoji Kumase, Fumiaki Morizane, Yuki Suzuki, Jun Kayama, Maki Brodowska, Katarzyna Nakazawa, Mitsuru Miller, Joan W. Connor, Kip M. Vavvas, Demetrios G. EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay |
title | EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay |
title_full | EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay |
title_fullStr | EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay |
title_full_unstemmed | EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay |
title_short | EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay |
title_sort | egf-like-domain-7 is required for vegf-induced akt/erk activation and vascular tube formation in an ex vivo angiogenesis assay |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960138/ https://www.ncbi.nlm.nih.gov/pubmed/24647208 http://dx.doi.org/10.1371/journal.pone.0091849 |
work_keys_str_mv | AT takeuchikimio egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT yanairyoji egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT kumasefumiaki egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT morizaneyuki egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT suzukijun egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT kayamamaki egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT brodowskakatarzyna egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT nakazawamitsuru egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT millerjoanw egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT connorkipm egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay AT vavvasdemetriosg egflikedomain7isrequiredforvegfinducedakterkactivationandvasculartubeformationinanexvivoangiogenesisassay |